Skip to main content
. 2020 Sep 28;13(10):277. doi: 10.3390/ph13100277

Table 2.

Inhibitors for CoV PLpro.

Inhibitor CoV Inhibition of (IC50, µM) Ref.
Pro 1 Ub 2 ISG15 3
Naphthalene inhibitors
Inline graphic 		SARS-CoV-2 2.4 ± 0.02 0.74 ± 0.07 1.50 ± 0.08 [28,96,97,110]
SARS-CoV 0.15 ± 0.01 0.66 ± 0.08 0.66 ± 0.09
MERS-CoV N.d. 4 N.d. N.d.
Ebselen
Inline graphic 		SARS-CoV-2 N.d. 2.02 ± 1.02 N.d. [99]
SARS-CoV N.d. 8.45 ± 0.96 N.d.
MERS-CoV N.d. N.d. N.d..
Tanshinones from S. miltiorrhiza
Inline graphic 		SARS-CoV-2 N.d. N.d. N.d. [64]
SARS-CoV 0.8 ± 0.2 0.7 ± 0.2 N.d.
MERS-CoV N.d. N.d. N.d.
Chalcones and coumarins from A. keiskei
Inline graphic 		SARS-CoV-2 N.d. N.d. N.d. [67]
SARS-CoV 1.2 ± 0.4 2.6 ± 0.7 1.1 ± 0.6
MERS-CoV N.d. N.d. N.d.
Zn2+-ion and conjugates
Inline graphic 		SARS-CoV-2 N.d. N.d. N.d. [62]
SARS-CoV 1.3 ± 0.2 N.d. N.d.
MERS-CoV N.d. N.d. N.d.
Diarylheptanoids from A. japonica
Inline graphic 		SARS-CoV-2 N.d. N.d. N.d. [65]
SARS-CoV 4.1 ± 0.3 3.0 ± 1.1 N.d.
MERS-CoV N.d. N.d. N.d.
Polyphenols from B. papyrifera
Inline graphic 		SARS-CoV-2 N.d. N.d. N.d. [68]
SARS-CoV 3.7 ± 1.6 7.6 ± 0.4 8.5 ± 1.2
MERS-CoV 39.5 ± 5.1 N.d. N.d.
N-Ethylmaleimide
Inline graphic 		SARS-CoV-2 N.d. N.d. N.d. [70,111]
SARS-CoV N.d. 4.4 ± 1.0 N.d.
MERS-CoV 45.0 ± 10.1 N.d. N.d.
Geranylated flavonoids from P. tomentosa
Inline graphic 		SARS-CoV-2 N.d. N.d. N.d. [66]
SARS-CoV 5.0 ± 0.06 N.d. N.d.
MERS-CoV N.d. N.d. N.d.
Thiopurine compounds 5
Inline graphic 		SARS-CoV-2 N.d. N.d. N.d. [70,111]
SARS-CoV N.d. 5.0 ± 1.7 N.d.
MERS-CoV 24.4 ± 4.3 12.4 ± 1.9 N.d.
8-(Trifluoromethyl)-9H-purin-6-amine
Inline graphic 		SARS-CoV-2 N.d. N.d. N.d. [69]
SARS-CoV 10.9 ± 0.9 N.d. N.d.
MERS-CoV 6.2 ± 0.9 N.d. N.d.
Disulfiram
Inline graphic 		SARS-CoV-2 N.d. N.d. N.d. [72]
SARS-CoV 14.2 ± 0.5 24.1 ± 1.8 N.d.
MERS-CoV 22.7 ± 0.5 14.6 ± 0.3 N.d.

1 Proteolytic activity; 2 deubiquitinating activity; 3 deISGylating activity; 4 not determined; 5 FDA-approved drugs indicated in green.